A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice

The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Mice received ibotenic acid or sham lesions to the nucleus basalis magnocellularis (nBM). Groups of nBM-lesioned and control mice were then trained on a modified Morris sw...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology, biochemistry and behavior biochemistry and behavior, 1988-09, Vol.31 (1), p.141-147
Hauptverfasser: Sweeney, Joanne E., Höhmann, Christine F., Moran, Timothy H., Coyle, Joseph T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 147
container_issue 1
container_start_page 141
container_title Pharmacology, biochemistry and behavior
container_volume 31
creator Sweeney, Joanne E.
Höhmann, Christine F.
Moran, Timothy H.
Coyle, Joseph T.
description The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Mice received ibotenic acid or sham lesions to the nucleus basalis magnocellularis (nBM). Groups of nBM-lesioned and control mice were then trained on a modified Morris swim maze task. Each mouse was first placed on a platform and then into quadrants of the swim tank in a random order. Time required to find the hidden platform was measured. In different phases of testing, the animal had to find a platform that either remained in the same quadrant (reference memory component) or was moved daily (working memory component). The nBM-lesioned mice took significantly longer to find the platform as compared to controls on the working, but not on the reference, memory component of the task. Galanthamine (5.0 mg/kg, IP), given 3.5 hours before testing, improved performance on the working memory task in nBM-lesioned mice by 70% and strikingly impaired performance in controls. Galanthamine's ability to reverse cognitive deficits induced by nBM lesions and its comparatively long half-life suggest that it may be effective in treating the central cholinergic deficits in Alzheimer's disease patients.
doi_str_mv 10.1016/0091-3057(88)90325-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78773139</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0091305788903255</els_id><sourcerecordid>78773139</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-99126da19e4ed6f2880aa3edcb01708c1b31ea94c6ba81cbf7e2ca671dd7a88c3</originalsourceid><addsrcrecordid>eNqFkE1r3DAQhkVJSTfb_oMGfAglObjVWLIlXwJhSdJCIJf2LMajcaLgj63kDey_r7e77DE5zeF93pfhEeIryO8gofohZQ25kqW5tPaqlqoo8_KDWIA1Ki_BmBOxOCKfxFlKL1JKXVTmVJzOcFFovRCPN1k3Dk850hSGp4yexy4MnCaOmDgLw3NowjTGLPIrx8QpS2ucAnZZz_0Yt5nnNlCY0oxmfSD-LD622CX-crhL8efu9vfqZ_7weP9rdfOQkwYz5XUNReURatbsq7awViIq9tRIMNISNAoYa01VgxaoaQ0XhJUB7w1aS2opvu1313H8u5kfdn1IxF2HA4-b5Iw1RoGq3wWhlFaXpZ5BvQcpjilFbt06hh7j1oF0O-FuZ9PtbDpr3X_hrpxr54f9TdOzP5YOhuf84pBjIuzaiAOFdMSMkrWVasau9xjP0l4DR5co8EDsQ2SanB_D23_8A7BznNY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15084554</pqid></control><display><type>article</type><title>A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sweeney, Joanne E. ; Höhmann, Christine F. ; Moran, Timothy H. ; Coyle, Joseph T.</creator><creatorcontrib>Sweeney, Joanne E. ; Höhmann, Christine F. ; Moran, Timothy H. ; Coyle, Joseph T.</creatorcontrib><description>The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Mice received ibotenic acid or sham lesions to the nucleus basalis magnocellularis (nBM). Groups of nBM-lesioned and control mice were then trained on a modified Morris swim maze task. Each mouse was first placed on a platform and then into quadrants of the swim tank in a random order. Time required to find the hidden platform was measured. In different phases of testing, the animal had to find a platform that either remained in the same quadrant (reference memory component) or was moved daily (working memory component). The nBM-lesioned mice took significantly longer to find the platform as compared to controls on the working, but not on the reference, memory component of the task. Galanthamine (5.0 mg/kg, IP), given 3.5 hours before testing, improved performance on the working memory task in nBM-lesioned mice by 70% and strikingly impaired performance in controls. Galanthamine's ability to reverse cognitive deficits induced by nBM lesions and its comparatively long half-life suggest that it may be effective in treating the central cholinergic deficits in Alzheimer's disease patients.</description><identifier>ISSN: 0091-3057</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/0091-3057(88)90325-5</identifier><identifier>PMID: 3252244</identifier><identifier>CODEN: PBBHAU</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Acetylcholinesterase ; Animal models for Alzheimer's disease ; Animals ; Behavior, Animal - drug effects ; Biological and medical sciences ; Cerebral Cortex - drug effects ; Cerebral Cortex - enzymology ; Cerebral Cortex - pathology ; Choline O-Acetyltransferase - analysis ; Cholinergic system ; Cholinesterase Inhibitors - pharmacology ; Galantamine - pharmacology ; Galanthamine ; Male ; Medical sciences ; Memory, Short-Term - drug effects ; Mice ; Mice, Inbred BALB C ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Nucleus basalis lesions ; Pharmacology. Drug treatments ; Spatial memory</subject><ispartof>Pharmacology, biochemistry and behavior, 1988-09, Vol.31 (1), p.141-147</ispartof><rights>1988 Pergamon Press plc</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-99126da19e4ed6f2880aa3edcb01708c1b31ea94c6ba81cbf7e2ca671dd7a88c3</citedby><cites>FETCH-LOGICAL-c417t-99126da19e4ed6f2880aa3edcb01708c1b31ea94c6ba81cbf7e2ca671dd7a88c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0091-3057(88)90325-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7309803$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3252244$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sweeney, Joanne E.</creatorcontrib><creatorcontrib>Höhmann, Christine F.</creatorcontrib><creatorcontrib>Moran, Timothy H.</creatorcontrib><creatorcontrib>Coyle, Joseph T.</creatorcontrib><title>A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Mice received ibotenic acid or sham lesions to the nucleus basalis magnocellularis (nBM). Groups of nBM-lesioned and control mice were then trained on a modified Morris swim maze task. Each mouse was first placed on a platform and then into quadrants of the swim tank in a random order. Time required to find the hidden platform was measured. In different phases of testing, the animal had to find a platform that either remained in the same quadrant (reference memory component) or was moved daily (working memory component). The nBM-lesioned mice took significantly longer to find the platform as compared to controls on the working, but not on the reference, memory component of the task. Galanthamine (5.0 mg/kg, IP), given 3.5 hours before testing, improved performance on the working memory task in nBM-lesioned mice by 70% and strikingly impaired performance in controls. Galanthamine's ability to reverse cognitive deficits induced by nBM lesions and its comparatively long half-life suggest that it may be effective in treating the central cholinergic deficits in Alzheimer's disease patients.</description><subject>Acetylcholinesterase</subject><subject>Animal models for Alzheimer's disease</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - enzymology</subject><subject>Cerebral Cortex - pathology</subject><subject>Choline O-Acetyltransferase - analysis</subject><subject>Cholinergic system</subject><subject>Cholinesterase Inhibitors - pharmacology</subject><subject>Galantamine - pharmacology</subject><subject>Galanthamine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Memory, Short-Term - drug effects</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Nucleus basalis lesions</subject><subject>Pharmacology. Drug treatments</subject><subject>Spatial memory</subject><issn>0091-3057</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1r3DAQhkVJSTfb_oMGfAglObjVWLIlXwJhSdJCIJf2LMajcaLgj63kDey_r7e77DE5zeF93pfhEeIryO8gofohZQ25kqW5tPaqlqoo8_KDWIA1Ki_BmBOxOCKfxFlKL1JKXVTmVJzOcFFovRCPN1k3Dk850hSGp4yexy4MnCaOmDgLw3NowjTGLPIrx8QpS2ucAnZZz_0Yt5nnNlCY0oxmfSD-LD622CX-crhL8efu9vfqZ_7weP9rdfOQkwYz5XUNReURatbsq7awViIq9tRIMNISNAoYa01VgxaoaQ0XhJUB7w1aS2opvu1313H8u5kfdn1IxF2HA4-b5Iw1RoGq3wWhlFaXpZ5BvQcpjilFbt06hh7j1oF0O-FuZ9PtbDpr3X_hrpxr54f9TdOzP5YOhuf84pBjIuzaiAOFdMSMkrWVasau9xjP0l4DR5co8EDsQ2SanB_D23_8A7BznNY</recordid><startdate>19880901</startdate><enddate>19880901</enddate><creator>Sweeney, Joanne E.</creator><creator>Höhmann, Christine F.</creator><creator>Moran, Timothy H.</creator><creator>Coyle, Joseph T.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19880901</creationdate><title>A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice</title><author>Sweeney, Joanne E. ; Höhmann, Christine F. ; Moran, Timothy H. ; Coyle, Joseph T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-99126da19e4ed6f2880aa3edcb01708c1b31ea94c6ba81cbf7e2ca671dd7a88c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Acetylcholinesterase</topic><topic>Animal models for Alzheimer's disease</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - enzymology</topic><topic>Cerebral Cortex - pathology</topic><topic>Choline O-Acetyltransferase - analysis</topic><topic>Cholinergic system</topic><topic>Cholinesterase Inhibitors - pharmacology</topic><topic>Galantamine - pharmacology</topic><topic>Galanthamine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Memory, Short-Term - drug effects</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Nucleus basalis lesions</topic><topic>Pharmacology. Drug treatments</topic><topic>Spatial memory</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sweeney, Joanne E.</creatorcontrib><creatorcontrib>Höhmann, Christine F.</creatorcontrib><creatorcontrib>Moran, Timothy H.</creatorcontrib><creatorcontrib>Coyle, Joseph T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sweeney, Joanne E.</au><au>Höhmann, Christine F.</au><au>Moran, Timothy H.</au><au>Coyle, Joseph T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>1988-09-01</date><risdate>1988</risdate><volume>31</volume><issue>1</issue><spage>141</spage><epage>147</epage><pages>141-147</pages><issn>0091-3057</issn><eissn>1873-5177</eissn><coden>PBBHAU</coden><abstract>The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Mice received ibotenic acid or sham lesions to the nucleus basalis magnocellularis (nBM). Groups of nBM-lesioned and control mice were then trained on a modified Morris swim maze task. Each mouse was first placed on a platform and then into quadrants of the swim tank in a random order. Time required to find the hidden platform was measured. In different phases of testing, the animal had to find a platform that either remained in the same quadrant (reference memory component) or was moved daily (working memory component). The nBM-lesioned mice took significantly longer to find the platform as compared to controls on the working, but not on the reference, memory component of the task. Galanthamine (5.0 mg/kg, IP), given 3.5 hours before testing, improved performance on the working memory task in nBM-lesioned mice by 70% and strikingly impaired performance in controls. Galanthamine's ability to reverse cognitive deficits induced by nBM lesions and its comparatively long half-life suggest that it may be effective in treating the central cholinergic deficits in Alzheimer's disease patients.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>3252244</pmid><doi>10.1016/0091-3057(88)90325-5</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-3057
ispartof Pharmacology, biochemistry and behavior, 1988-09, Vol.31 (1), p.141-147
issn 0091-3057
1873-5177
language eng
recordid cdi_proquest_miscellaneous_78773139
source MEDLINE; Elsevier ScienceDirect Journals
subjects Acetylcholinesterase
Animal models for Alzheimer's disease
Animals
Behavior, Animal - drug effects
Biological and medical sciences
Cerebral Cortex - drug effects
Cerebral Cortex - enzymology
Cerebral Cortex - pathology
Choline O-Acetyltransferase - analysis
Cholinergic system
Cholinesterase Inhibitors - pharmacology
Galantamine - pharmacology
Galanthamine
Male
Medical sciences
Memory, Short-Term - drug effects
Mice
Mice, Inbred BALB C
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Nucleus basalis lesions
Pharmacology. Drug treatments
Spatial memory
title A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T18%3A12%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20long-acting%20cholinesterase%20inhibitor%20reverses%20spatial%20memory%20deficits%20in%20mice&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Sweeney,%20Joanne%20E.&rft.date=1988-09-01&rft.volume=31&rft.issue=1&rft.spage=141&rft.epage=147&rft.pages=141-147&rft.issn=0091-3057&rft.eissn=1873-5177&rft.coden=PBBHAU&rft_id=info:doi/10.1016/0091-3057(88)90325-5&rft_dat=%3Cproquest_cross%3E78773139%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15084554&rft_id=info:pmid/3252244&rft_els_id=0091305788903255&rfr_iscdi=true